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ABSTRACT 
Objective: The aim of the present study was to investigate the mode and mechanism of interactions involved towards binding of valganciclovir 
(VGC) with Human Serum Albumin (HSA) by spectroscopic and molecular modeling studies which can be extrapolated for the ten folds increase of 
bioavailability over its prodrug galanciclovir. 
Methods: Herein we employed fluorescence spectroscopy for evaluating the binding constant value, site of interaction and changes in the 
microenvironment of HSA fluorophores. Circular dichroism (CD) and UV-Visible spectroscopy is used for conformational changes of HSA in the 
event of binding of valaganciclovir. These experimental studies were further corroborated with molecular modeling studies.  
Results: Considerable quenching of fluorescence intensities of fluorophores in the presence of VGC showed that VGC interacts with HSA strongly 
with a binding constant of 4.11x104 M-1
Conclusion: The weaker dominant electrostatic interactions with minor contributions of hydrophobic interactions of VGC with HSA at site IB 
(catalytic domain) might be the probable reason for the relative increase of hydrolysis of VGC to galanciclovir. And moderate binding constant value 
with HSA implies that HSA can be able to transport VGC under physiological conditions.  
 with a free energy change of-6.26 Kcal/mol. Synchronous fluorescence and CD studies show that the 
microenvironment and confirmation of HSA are slightly altered in the presence of VGC. Though site marker experiments does not give any clue for 
identification of site, molecular docking studies showed that VGC binds to site IB of HSA. 
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Diseases that are prevailing and emerging due to infections are rapidly 
increasing in the present day due to the confluence of socio-economic 
factors. Among the infections, viral infections form the huge burden to 
many countries including India. Though few of these viral infections 
are combated up to some extent, cytomegalovirus (CMV) which 
belongs to the herpes virus is still at the get-go stage of combat due to 
lack of complete understanding of the biology of CMV infections. Till 
date, it is believed that the mode of infection of CMV also follows the 
modes through which the human immune deficiency virus (HIV) is 
transmitted. And pity part of the infection is that it causes no 
symptoms at its initial infection and can only show symptoms during 
the stage of compromising the immune system (i. e during 
coinfections). CMV infected patients when co-infected with HIV leads 
to visual loss. Hence there is an urgent need to develop new antiviral 
drugs for treating CMV infections. Presently, the medications used for 
the treatment of CMV is very limited, and among them, galanciclovir 
[1, 2] foscarnet [2, 3] or cidofovir [4, 5] are routinely used 
intravenously. Limitations pertaining to the use of these drugs are due 
to the poor bioavailability and development of resistant by CMV upon 
prolonged administration of these drugs. In this line, valganciclovir 
(VGC, fig. 1A.) a prodrug of ganciclovir is developed. VGC is 
hydrochloride salt, which exists as a mixture of diastereomers, is L-
valyl ester of ganciclovir, which upon oral administration rapidly 
hydrolysis into active forms of ganciclovir in the presence of hepatic 
and intestinal esterases. Intracellularly, the active form of galancicovir 
was further phosphorylated leading to more active form galanciclovir 
triphosphate, thereby inhibiting the viral DNA replication [6]. The 
success of VGC over other antiviral drugs in treating CMV is due to its 
high bioavailability. It was demonstrated that the absolute 
bioavailability of CMV is 60%, which are ten folds higher than 
galanciclovir if administrated orally [7, 8]. This improved efficacy is 
thought to be due to the presence of valine which mediates the active 
transportation of VGC to the site of action [9]. This further reiterates 
that most of the bioavailability of drugs depend on the binding 
strength towards transporting proteins besides the binding strength 
towards target sites (proteins/DNA). For many compounds, either 
administrated orally or intravenously, the first major sight of 
encountering proteins with the drugs is plasma proteins. Among the 
plasma proteins, human serum albumin (HSA) provides a terminus in 
such a way that the drugs will be available beyond their soluble 




Fig. 1: A) Chemical structure of valganciclovir (VGC) and B) 3D 
Structure of human serum albumin (HSA) 
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HSA a non-glycosylated single polypeptide chain allosteric protein fig. 
1B consists of 585 amino acids and resembles a heart shape three-
dimensionally. Structurally, the protein is divided into three domains I 
(residues 1-195), II (196-383) and III (384-585) with 17 disulfide 
bridges. HSA is known to bind to a variety of both exogenous and 
endogenous drugs with high affinities. This high affinity are attributed 
to its allosteric nature thereby forming an important determinant for 
evaluating the pharmacokinetic behaviour of many drugs. Since HSA 
will be synthesized and secreted from liver cells, we presume that the 
binding nature of VGC towards HSA might alter the hepatic esterase 
activity of hydrolyzing VGC to its prodrug galancicolvir. To the best of 
our knowledge, till date, there are no reports wherein the binding 
properties of VGC towards HSA are studied. Hence in the present 
study, we aim to study the binding studies of VGC towards HSA by 
multi spectroscopic and computational studies. 
MATERIALS AND METHODS 
Materials 
Valganciclovir (VGC) is procured as a gift sample from Laurel 
pharma labs, Hyderabad, India. Stock Solution of 1 mmol VGC is 
prepared in DMSO and further diluted with 100 mmol saline 
phosphate buffer (pH=7.4) in order to have a working stock solution 
of 0.1 mmol. Site markers, phenylbutazone (PB) and ibuprofen (IB) 
are also prepared in a similar manner. HSA (fatty-acid free) is 
purchased from Sigma Aldrich. The Stock solution of HSA (0.1 mmol) 
is prepared in saline phosphate buffer (100 mmol) at a pH of 7.4. All 
solvents used in the study were of analytical grade.  
Methods  
All the working solutions are 1µM of HSA and VGC are titrated from 
1 to 10µM for all the experiments performed unless mentioned. The 
UV-Vis spectra of the VGC-HSA mixtures was monitored over the 
wavelength range of 220–350 nm using a double beam UV-Vis 
spectrophotometer (UV-1800ShimadzuTM) (Shimadzu Corporation, 
Tokyo, Japan). 
Steady-state fluorescence studies were carried out on Jasco J-815 
spectropolarimeter equipped with Peltier thermostat, using a quartz 
cell of the path length of 1 cm. An Excitation wavelength of 280 nm is 
used for exciting both tryptophan and tyrosine, and emission 
spectra was recorded from 300-500 nm. Excitation and emission 
bandwidths are set at 5 nm and 10 nm respectively. Further, the 
detector voltage is set at 550V. All the spectra obtained are the 
average of three accumulations with a data pitch of 1 nm and a scan 
speed of 100 nm/min. In order to reduce the probable absorption of 
emitted light by VGC, which affects the emitted light (inner filter 
effect), the obtained fluorescence spectra were corrected for the 
inner filter effect by the following equation. 
FCor = F Obs × e(Aexi+Aemi)/2 
Wherein Fcor and Fobs are the corrected and observed fluorescence 
intensities respectively, and Aexi and Aemi
Molecular modelling studies were performed using autodock 4.2 
program using a lamarckian genetic algorithm. HSA X-ray crystal 
structure is taken from brookhaven protein data bank (PDB ID: 
1AO6) and the protein topology was prepared using autodock 4.2. 
PBD structure of valganciclovir is obtained from https://www. 
drugbank.ca/drugs/DB01610 and is used without further 
modifications. Grid box of dimensions 126 x 126 x 126 was set with 
a grid spacing of 0.703 A °. And the center of the grid was set to 2.95, 
3.18 and 2.35 nm. Docking parameters were set at default settings, 
and 25 conformations were run using a genetic algorithm. The 
conformer with the lowest binding energy that corresponds to the 
experimental value is visualized and analyzed using PyMol software. 
 are the respective 
absorbance intensities of excitation and emission wavelengths of 
HSA protein. Site identification studies were also performed under 
similar conditions. For temperature studies, the cell temperature of 
273, 293 and 303 °K is maintained using nitrogen gas under above-
mentioned conditions. Synchronous experiments (∆λ=15 and 
∆λ=60) were carried on LS55 spectrofluorometer, PerkinElmer 
corporate, USA with an excitation and emission slit widths of 8 nm 
and 10 nm respectively with a scan speed of 100 nm/min over the 
wavelength range of 200-350 nm. The spectra obtained are the 
average of three scans.  
CD measurements were also carried on the above instrument (Jasco 
J-815 spectropolarimeter) using a quartz cell length of 0.2 cm in the 
far UV range (190-300 nm) at room temperature. CDNN 2.1 software 
is used for evaluation of structural changes. 
RESULTS AND DISCUSSION 
UV-visible analysis 
In an initial attempt, we employed UV-Visible spectroscopy towards 
understanding the binding interactions of HSA with VGC. From fig. 2 
it is evident that HSA showed two significant absorption peaks at 
200-210 nm and 260-300 nm which are fingerprint regions for the 
predicting secondary structural changes and the microenvironment 
of intrinsic chromophores respectively. Sequential addition of 1µMof 
VGC to the final concentration of 10µM of VGC leads to a gradual 
increase in the intensity of the absorption peak at 280 nm. Though 
the increase is very marginal these are significant for understanding 
the changes in the microenvironment of the aromatic residues. 
Secondly, there is a marginal red shift in 200-210 nm along with the 
increase in the intensity of the absorption. This result suggests that 
the polarity of aromatic amino acid residues, particularly trp-214, 
protein backbone conformation and α-helix content of HSA might be 
slightly altered with the addition of VGC. To further elucidate and to 
affirm structural changes of HSA during interaction with VGC, 
Circular dichroism (CD) studies were employed. 
 
 
Fig. 2: UV-visible spectra of HSA (1µM) with varying 
concentrations of VGC (1-10µM) 
 
Circular dichroism analysis 
CD spectral analysis of HSA showed two characteristic negative 
peaks at 208 and 222 nm that corresponds to α-helix content of the 
native protein. Sequential addition of 1µM of VGC to HSA resulted in 
the increase of the intensity of these two peaks fig. 3A. However, 
such an increase in intensity is very marginal indicating that the 
secondary structural elements of HSA are well preserved during the 
interaction with VGC thereby not affecting the transporting 
capability of HSA. Similar observations were made in the recent 
studies, wherein the α-helical content of HSA is reduced to a lesser 
extent during interaction with drugs [10, 11]. Further, the extent of 
decrease in the α-helical content is quantified. The percentage of α-
helix in the native state is found to be ~67.9% and gradually 
decreased to ~63% while β-sheets and random coils are increased 
from 18.1 to 20%, 14.8 to 18.3% respectively during the course of 
VGC titrations fig. 3B. This result indicates that the 
microenvironment of the protein is changed and the compactness of 
the protein is reduced during the interaction with VGC. These 
observations further corroborate with that of UV spectral analysis.
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Fig. 3: CD Spectra of A) HSA (1µM) with varying concentrations of VGC (1-10µM) B) secondary structural changes of HSA in the presence of 
VGC (1-10µM) 
 
Fluorescence spectroscopic analysis 
Synchronous fluorescence 
In addition to UV-Visible spectroscopy and CD analysis, an alternative 
approach to ascertain the changes in the microenvironment of 
fluorophore residues of proteins during binding with the drugs is to 
study synchronous fluorescence behavior of fluorophores. 
Synchronous fluorescence in its simplest form is a way of scanning 
emission and excitation monochromators simultaneously with the 
fixed interval of wavelengths (∆λ=15 nm for tyrosine and ∆λ=60 nm 
for tryptophan). Possible shifts in the emission maxima reveal the 
hydrophobicity of fluorophores environment [12-14]. Accordingly, in 
the present study synchronous fluorescence spectra at a fixed 
wavelength intervals of 15 nm and 60 nm were studied. Fig. 4A shows 
that there are no considerable shifts in emission maxima at ~285 nm 
which imply that the microenvironment of tyrosine residues are not 
altered much due to binding of VGC with HSA. However, synchronous 
fluorescence spectra at a fixed wavelength interval of 60 nm fig. 4B 
showed a marginal blue shift of ~3 nm indicating that the 
microenvironment of tryptophan residue is slightly altered due to the 
presence of VGC in the close proximity. Hence these results are 
consistent with those of UV and CD spectral studies. 
  
 
Fig. 4: Synchronous spectra of VGC with HSA A) ∆λ=15 nm and B) ∆λ=60 nm with increasing concentrations of VGC (1-10µM) 
 
Quenching mechanism and binding constant evaluation 
Besides the above techniques that were mentioned and discussed, 
fluorescence spectroscopy provides an excellent platform for 
screening and understanding the nature of binding interactions 
between protein and small molecules by taking advantage of 
intrinsic fluorophores such as tryptophan, tyrosine, and 
phenylalanine. Presence of single tryptophan residue in the given 
protein is fairly enough for performing fluorescence since it is 
having high quantum yield when compared to other amino acids. In 
addition to understanding the binding interactions, binding 
constants, binding sites, and the effect of temperature on the binding 
mode can also be evaluated with the aid of this technique. Hence in 
the present study, we adopted and employed this technique for 
further screening of binding interactions of HSA with VGC. 
Titration of VGC with HSA in increments of 1µM resulted in a 
sequential decrease of fluorescence intensity at 340 nm fig. 5. 
Without considerable shifts in emission maximum and/or emission 
peak shapes. Such observations indicate that interactions exist 
between VGC and HSA and compliments with those of the results 
that are obtained from UV-Visible studies and conformational 
analysis. Further, this gradual decrease of fluorescence intensity or 
quenching suggests that VGC is interacting with HSA at the site, 
which is at the vicinity of trp-214. 
 
Fig. 5: Fluorescence spectra of HSA in the presence of increasing 
concentrations of VGC (1-10µM) 
 
It is evident from the literature [15-17] that the process of 
quenching takes place via either through statically or dynamically 
during protein-drug interactions. Static quenching process can be 
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differentiated from dynamic quenching process by examining the 
quenching rate constants at different temperatures [18] or by 
calculating the lifetime of the fluorophore in the excited states. 
Towards understanding the quenching mechanism involved during 
the interaction of VGC with HSA we applied the well-known Stern-
volmer equation as below. 
Fo/F = 1+Kqτ0[Q] = 1+KSV
Where, F
[Q] 
o and F are fluorescence intensities of fluorophore in the 
absence and presence of VGC, [Q] is concentration of quencher in 
this case it is [VGC], kq is bimolecular quenching rate constant, τ0-
lifetime of the fluorophore (~10-8s) in the absence of VGC and KSV 
K
is 
Stern–volmer quenching constant and can be obtained as given 
below 
q = Ksv/τ
From the plot of F
0. 
o/F vs [VGC] the stern-volmer quenching constant 
was found to be 3.4 x 1012 M-1s-1 and is far larger than maximum 
diffusion collisional quenching rate constant for various quenchers 
in the presence of biopolymers 2.0 x 1010 M-1s-1
  
. 
Table 1: Stern–volmer (Ksv), quenching constant (Kq), binding constant (Kb
T (°K) 
) and free energy (ΔG °) of VGC–HAS complex at 293 and 303 °K 
293 °K 303 °K 
Ksv x 104(M-1 3.51 ) 6.38 
Kq x 1012(M-1. s-1 3.51 ) 6.38 
R 0.99 2 0.98 
Kbx 104(M-1 3.95 ) 3.32 
Binding sites (n) 1.02 0.87 
R 0.99 2 0.96 
ΔG ° (Kcal/mol) -6.24 -6.14 
 
 
Fig. 6: Stern-volmer plots for VGC-HSA complex at 293 and 303 ° K 
 
Therefore the interaction of VGC with HSA follows a static quenching 
mechanism [19]. In order to further ascertain this quantitatively, 
stern-volmer constants were evaluated at two different 
temperatures (293 °K and 303 °K). From table 1 and fig. 6 it is 
evident that there is an increase in the stern-volmer constants with 
the increase in temperature, which demonstrates that the 
mechanism involved in the formation of HSA-VGC complex is due to 
dynamic collision rather than complex formation. This is in contrary 
to that of lifetime measurements of fluorophores. The mechanism of 
static and/or dynamic complex formation can be further confirmed 
by taking the difference in the absorption spectra of HSA-VGC 
complex and the VGC absorption [20]. Since static quenching is the 
result of the complex formation of the HSA-VGC in the ground state, 
the difference in the absorption spectra near ultraviolet region (250-
400 nm) of HSA-VGC complex and VGC is significant. This result 
further illustrates that the quenching mechanism involved in the 
HSA-VGC complex is by static quenching (data not shown).  
For evaluating the binding strength and number of binding sites, the 
modified stern-volmer equation is used. 
Log (F0
Where K, n and [Q] represents binding constant, number of binding 
sites and concentration of VGC respectively. From double reciprocal 
log plots, the binding constant is found to be 4.11 x 10
−F)/F = log K+n log [Q] 
4 M-1
ΔG ° =-RT ln K 
 and the 
number of binding sites is found to be 1.0. This data indicates that 
VGC and HSA form a moderately strong complex with one binding 
site. Since the complex formation is driven by intermolecular forces 
such as van der Waals, hydrogen bonds, hydrophobic forces and 
electrostatic forces which contribute to the free energy change for 
the complex formation hence standard free energy for the complex 
formation is calculated by the following equation. 
Where ΔG ° is free energy change, R is the gas constant and K is the 
binding constant of VGC at temperature T °K. The calculated free 
energy change is found to be-6.27 Kcal/mol during the interaction of 
VGC with HSA and the negative sign implies that the complex 
formation is spontaneous wherein hydrogen bonding and 
hydrophobic interactions play a major role during complex 
formation. 
Nature of binding forces involved in binding mode 
Non-covalent interactions, namely Van derWaals forces, electrostatic 
forces, hydrophobic interactions and hydrogen bonds are the 
principal driving forces that are involved during complex formation 
between protein and drug. Depending on the nature of functional 
groups present in the drug, aforementioned forces dominate over 
other and contribute to thermodynamic parameters such as 
enthalpy (ΔH) and entropy (ΔS) changes during complex formation 
[20]. Hence for further elucidating these driving forces that are 
involved in complex formation between VGC and HSA 
thermodynamic parameters were calculated using Van’t Hoff 
equation which is given as below. 
InK =-∆H °/RT+∆S °/R 
∆G ° = ∆H °-T∆S ° 
Where K is the binding constant at the temperature T and R is the 
gas constant and the values of ∆H ° and ∆S ° were evaluated from the 
slope and intercept of the plots of ln K against 1/T. Thermodynamic 
parameters at temperatures 293 and 303 °K were evaluated and 
found that a small negative value (-12.82 kJ/mol) of enthalpy and 
positive value (44.22 J/mol K) of entropy were associated with the 
complex formation between VGC and HSA, which implies that 
complex formation between HSA and VGCis driven by electrostatic 
interactions. However, the contributions of hydrophobic 
interactions for positive entropy cannot be ignored [24]. The 
negative values of ∆G  ° at the studied temperatures (-6.24 and-6.14 
Kcal/mole, respectively, table 1) also indicates the complex 
formation is spontaneous with the large contribution of entropy and 
with small contribution from enthalpy. 
Binding site identification 
Being allosteric in nature, HSA possesses more than one binding site 
and therefore forms a major depot for most of the exogenous and 
endogenous molecules. However, there are two primary drug 
binding sites namely site I (Sudlow site I) and site II (Sudlow site II) 
located in subdomains IIA and IIIA respectively. Besides these 
primary binding sites recently it was demonstrated that subdomain 
IB functions as the secondary binding site[22]. In order to identify 
the probable binding site of VGC with HSA, site displacement 
method was adopted [23]. Among the known site markers of HSA, 
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phenylbutazone (Pbz) and ibuprofen (Ibu) were used in the present 
study. Complexes of HSA-Pbz and HSA-Ibu are prepared by mixing 
1µM each and incubated for 5 min before titrating with VGC in 
increments of 1µM. From fig. 7A it is evident that the fluorescence 
intensity of HSA-Pbz complex gradually decreased by the addition of 
VGC without considerable blue/red shifts and the binding constant 
for VGC in the presence of Pbz is found to be 1.20 x 104 M-1. Such a 
decrease in the binding constant value implies that the VGC might be 
approaching near to the Pbz binding site i. e Sudlow site I. On the 
other hand, the addition of VGC to the complex of HSA-Ibu complex 
fig. 7B, there is also a gradual decrease in the fluorescence intensity, 
but the amount of quenching is relatively less in comparison to that 
of HSA-Pbz complex. And the binding constant value VGC is found to 
be 8.14 x 104 M-1
 
 in the presence of Ibu site marker. This implies that 
VGC might not be approaching the Ibu binding site i. e Sudlow site II 
[24]. Therefore, in order to further elucidate and confirm the 
binding site the complementary approach of molecular modeling is 
applied [25]. 
 
Fig. 7: Fluorescence spectra of VGC-HSA in the presence of site markers A) Phenylbutazone (Pbz) and B) Ibuprofen (Ibu) 
 
Molecular docking analysis 
Molecular docking approach provides complementary results that 
ameliorate the understanding of molecular interactions involved in 
the complex formation of HSA with VGC. Making use of this 
approach, twenty-five conformations of HSA-VGC complexes were 
generated in insilico conditions. Among the generated 
conformations, seven conformers are found to interact with site IB 
and are mostly buried in the groove while six conformers are found 
to interact with site IIIB, however, having high free energy when 
compared to the conformers that are bound to site IB. Further, only 
one conformer is found to bind to site IIA of HSA this reveals that 
VGC is not exactly competing for the site I but approaching to the 
site near to site I which is also in accordance with the decrease in the 
binding constant values. Furthermore, the free energy change (-5.32 
Kcal/mole) is close to the experimental values (-6.27 Kcal/mol) that 
are obtained from fluorescence. Therefore, among the seven 
conformers that are found to interact with the site IB the best 
docked stable conformer is subjected for further analysis. From fig. 8 
it is evident that VGC forms four hydrogen bonds with Try-161, Phe-
134, His-146 and Arg-186 with the bond distances of 2.9, 3.3, 2.2 and 
3.3A ° respectively which are at a favourable distance for formation 
strong hydrogen bonding. Further, the guanosine group of VGC is 
further stabilized by hydrophobic interactions with Lys-190, Ile-142, 
Leu-115, and Arg-186 whereas the ester functionality is interacting 
with Pro-118, Phe-134 and Met-123 hydrophobically within the 
distance of 4.2-5.5 A °. These results indicate that VGC is stabilized 
by dominant electrostatic interactions with little contributions of 
both hydrophobic and hydrophilic interactions which complement 
the results that are obtained from thermodynamic studies. 
 
 
Fig. 8: Schematic view of lowest binding energy docked conformer of VGC with HSA. Zoomed view showing hydrogen bonding distances 
along with interacting amino acids 
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CONCLUSION 
In the present study, we explored the binding interactions of VGC 
with HSA by spectroscopic and molecular modelling studies. A Slight 
red shift in UV-Visible analysis and minor/no changes in the 
synchronous fluorescence demonstrated that the microenvironment 
of HSA was changed marginally during interaction with HSA. Small 
changes in alpha-helical content by CD analysis further confirm this. 
Moreover, fluorescence quenching studies illustrate that complex 
formation takes place through a static quenching mechanism with a 
binding constant of 4.11x104 M-1
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